SITE015-0087

SITE015 (POL) › SITE015-0087

SITE015-0087

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2025-12-10

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-01 (study day 230); relationship: RELATED

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-11 (study day 148); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.